


The investment objective of the fund is to generate positive and uncorrelated absolute returns in all market conditions over a 12 month period.
| Name | % Net Assets | 
|---|---|
| GENENTECH INC (UN*) | 4.3% | 
| NOVO NORDISK A/S-B (DC*) | 3.3% | 
| NESTLE SA-REGISTERED (VX*) | 3.0% | 
| BRITISH AMERICAN TOBACCO PLC | 3.0% | 
| NATIONAL GRID PLC (LN*) | 2.6% | 
| GDF SUEZ (FP*) | 2.1% | 
| TERNA SPA (IM*) | 2.1% | 
| ACTELION LTD (SE*) | 2.1% | 
| FRESENIUS MEDICAL CARE (GF) | 2.0% | 
| NOVARTIS AG-REG SHS (VX*) | 2.0% | 
| Key | % Net Assets | 
|---|---|
| 4.3% | |
| 3.3% | |
| 3.0% | |
| 3.0% | |
| 86.4% | 
| Date | 24-Nov-2017 | 
|---|---|
| NAV | 92.25p | 
| Currency | GBP | 
| Change | -0.14p | 
| % | -0.15% | 
| YTD change | 92.25p | 
| YTD % | n/a | 
| Fund Inception | n/a | 
|---|---|
| Fund Manager | n/a | 
| TER | 1.88 (31-Dec-2011) | 
| Minimum Investment | |
|---|---|
| Initial | n/a | 
| Additional | n/a | 
| Savings | n/a | 
| Charges | |
|---|---|
| Initial | n/a | 
| Annual Mang't | 1.75% | 
| Exit | n/a | 
| Name | % | 
|---|---|
| No risk data available. | |
You are here: research